A Phase 3 interventional study of Phase1 : CDED/Modulen™IBD® + Maintenance therapy and Phase2 and 3 : in Crohn's Disease, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 4 sites in France. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-03-27.
Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Crohn Disease by Assistance Publique - Hôpitaux de Paris — 7 open to participants now, 8 under way, 3 of them phase 3. Crohn Disease · Assistance Publique - Hôpitaux de Paris.
Among the 19 studies in Crohn Disease by Assistance Publique - Hôpitaux de Paris, this one is the 4th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2022, is one of 2 in phase 3, and was the 13th registered.
1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.
Browse Crohn Disease studies →7 of the 19 studies in Crohn Disease by Assistance Publique - Hôpitaux de Paris are open now, in 2 countries. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–50 · Healthy volunteers
Assistance Publique - Hôpitaux de Paris · Sites in France
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–74 · Healthy volunteers
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
By country, each count listing its studies:
Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 3
First in 2004; this study’s year is marked. 2 started in 2022.
This study's planned enrollment of 120 is above the median of 67 across 1,262 interventional studies indexed under Crohn Disease.
Median enrollment 105 across the 12 interventional studies, 385 across the 6 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
3 of the studies in Crohn Disease by Assistance Publique - Hôpitaux de Paris that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04777656Phase 3Assistance Publique - Hôpitaux de ParisUse of Crohn's Disease Exclusion Diet on Top of Standard Therapy Versus Standard Therapy Alone in Unstable Pediatric Crohn's Disease Patients. | 2026-11 |
| NCT04997733Phase 3Assistance Publique - Hôpitaux de ParisFecal Microbiota Transplantation in Crohn's Disease as Relay After Anti-TNF Withdrawal | 2027-05-22 |
| NCT07300553Assistance Publique - Hôpitaux de ParisImpact Of The Gut Microbiota On Host Cells Energy Metabolism in Health And In Inflammatory Bowel Disease | 2026-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 19 studies in Crohn Disease by Assistance Publique - Hôpitaux de Paris, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This research is a multicenter French randomized and single blinded phase III clinical trial evaluating two treatment strategies among Crohn's disease (CD) patients. The main objective is to assess if the addition of Crohn's Disease Exclusion Diet (CDED) to ongoing standard medication is superior to reduce the rate of relapses over 12 months compared to standard medication alone in children/adolescents with unstable CD responding with remission after a 2-months course of CDED
Crohn's disease is a recurrent inflammatory disorder. Current treatment strategies aim reducing intestinal (and systemic) inflammation based on the use of Immunomodulators (IM) and biologics (B). However, some patients, particularly in the pediatric age group do not respond with remission to standard therapy and approximately 30% of patients lose response to efficient therapy. There is a clear unmet need for new treatment strategies. In addition, patients and families have a high degree of reluctance to use IM/B as life-long medication, particularly due to potential side effects including cancer, lymphomas, serious infections or drug-related immune diseases. This is of particular importance for children/adolescents with CD, potentially exposed over many decades to various IM/B. Experimental and epidemiological data indicate that the western life style and particularly modern food play a key role in the development of CD, probably via alteration of the intestinal barrier function and/or enforcing the intestinal dysbiosis. Based on these data and the observation that exclusive enteral nutrition is highly efficacious in inducing remission in active CD, nutritional therapies are more and more in the focus for the development of new treatment approaches.
The main objective is to assess if the addition of CDED to ongoing standard medication is superior to reduce the rate of relapses over 12 months compared to standard medication alone in children/adolescents with unstable CD responding with remission after a 2-months course of CDED.
To achieve this objective, eligible patients with active CD will participate to this study for a 13 months period. After a screening period, the patients will have a 2 months run-in phase where they will follow the CDED protocol, but continue their maintenance therapy, with the exception of corticosteroid that have to be tapered and stopped at the end of the 2 months.
Then, the patients responding to CDED during run-in will be randomized at M2 to one of the two treatment arms (CDED/Modulen™IBD® or Unrestricted food access) and will have 4 follow-up visits (M4, M6, M9 and M12)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Strategy combining CD exclusion diet plus Modulen™IBD® on top of ongoing maintenance therapy.
Dietary Supplement: Phase1 : CDED/Modulen™IBD® + Maintenance therapy · Dietary Supplement: Phase2 and 3 :
Stop CDED and Modulen™IBD®, but continue maintenance therapy with unrestricted food access.
Dietary Supplement: Phase1 : CDED/Modulen™IBD® + Maintenance therapy
Patient not in remission at M2 or refusing randomisation
Dietary Supplement: Phase1 : CDED/Modulen™IBD® + Maintenance therapy
from D0 until M2: Phase 1 (2 months run-in phase with CDED protocol + maintenance therapy, with the exception of corticosteroid that have to be tapered and stopped until M2.)
from M2 until M4 CDED phase 2 (introduction of a selected number of additional food). From M4 until end of the study CDED phase 3 (enlargement of number of additional foods and allowance of some initially excluded foods).
Also known as: CDED/Modulen™IBD® + Maintenance therapy
Relapse from randomization until M12
Relapse is defined as weighted Paediatric Crohn's disease activity index (wPCDAI) \>40 points and/or CRP \>2 times over upper limit (in the absence of any obvious infections sign) or if at two consecutive visits (within 2-8 weeks) the wPCDAI is \>12,5 but less 40 and/or CRP \>1,5 but less 2 times over upper limit (in the absence of any obvious infections sign) or if the patient required additional CD-specific medication/surgery in the interval.
Time frame: 12 months
Change of wPCDAI from baseline to M2
Time frame: 2 months
Change of fecal calprotectin values from baseline to M2
Time frame: 2 months
Clinical remission at M2
Defined as wPCDAI ≤12.5 and normal CRP (≤1.5 fold upper normal range)
Time frame: 2 months
Deep remission at M2
Defined as wPCDAI ≤12.5 and normal CRP within normal lab range) and normal fecal calprotectin ((\<250µg/g)
Time frame: 2 months
Physician global assessment (PGA) from baseline to M2
Crohn's Disease activity assessed as remission - weak - moderate - severe
Time frame: 2 months
Mucosal healing at M2
absence of any ulcerations (including aphthae)
Time frame: 2 months
Endoscopic response at M2
Decrease of Crohn's Disease Endoscopic Index Score (CDEIS) ≥ 50% from baseline
Time frame: 2 months
Change of MRI from baseline to M2
Simplified Magnetic Resonance Index of Activity (MARIA) for Crohn's Disease score from baseline to M2
Time frame: 2 months
CDED tolerance rate at M2
serious and non serious adverse events
Time frame: 2 months
CDED compliance rate at M2
Time frame: 2 months
Change of intestinal microbiome composition from baseline to M2
Time frame: 2 months
Clinical remission
Defined as wPCDAI ≤12.5 and normal CRP (≤1.5 fold upper normal range)
Time frame: At 4 months, 6 months, 9 months and 12 months
Deep remission
Defined as wPCDAI ≤12.5 and normal CRP (within normal lab range) and normal fecal calprotectin (\<250µg/g)
Time frame: At 4 months, 6 months, 9 months and 12 months
Relapse
Defined as wPCDAI \>40 points and/or CRP \>2 times over upper limit (in the absence of any obvious infections sign) or if at two consecutive visits (within 2-8 weeks) the wPCDAI is \>12,5 but less 40 and/or CRP \>1,5 but less 2 times over upper limit (in the absence of any obvious infections sign) or if the patient required additional CD-specific medication/surgery in the interval
Time frame: At 4 months, 6 months, 9 months and 12 months
Physician global assessment (PGA)
Crohn's Disease activity assessed as remission - weak - moderate - severe
Time frame: At 4 months, 6 months, 9 months and 12 months
Mucosal Healing at M12
Absence of any ulcerations (including aphthae)
Time frame: 12 months
Endoscopic response at M12
Decrease of Crohn's Disease Endoscopic Index Score (CDEIS) ≥ 50% from baseline
Time frame: 12 months
Change of MRI from M2 to M12
Simplified Magnetic Resonance Index of Activity (MARIA) for Crohn's Disease score from M2 to M12
Time frame: 12 months
CDED tolerance rate at M12
Serious and non serious adverse events
Time frame: 12 months
CDED compliance rate at M12
Time frame: 12 months
Change of Intestinal microbiome composition
Time frame: At 4 months, 6 months, 9 months, 12 months
Change of quality of life IMPACT-3 from inclusion until 12 months
IMPACT-3 questionnaire of 35 closed questions - scale ranging from 1 to 5 for all answers - higher score suggesting better quality of life
Time frame: At baseline, 2 months, 4 months, 6 months, 9 months, 12 months
Plan to share: No
Started Sep 2022 (actual). Primary completion is estimated for Nov 2026, 50 months after the start.
Of 88 phase 3 interventional studies under Crohn Disease, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 69. This study's planned 50 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →